{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:26:56Z","timestamp":1791473216602,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Forschungskommission of the Medical Faculty of the Heinrich Heine University D\u00fcsseldorf"},{"DOI":"10.13039\/501100014690","name":"Ministry of Culture and Science of North Rhine-Westphalia","doi-asserted-by":"crossref","award":["PROFILNRW-2020\u2013107-A"],"award-info":[{"award-number":["PROFILNRW-2020\u2013107-A"]}],"id":[{"id":"10.13039\/501100014690","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Regierenden B\u00fcrgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung"},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis is a chronic antibody-mediated autoimmune disease disrupting neuromuscular synaptic transmission. Informative biomarkers remain an unmet need to stratify patients with active disease requiring intensified monitoring and therapy; their identification is the primary objective of this study. We applied mass spectrometry-based proteomic serum profiling for biomarker discovery. We studied an exploration and a prospective validation cohort consisting of 114 and 140 anti-acetylcholine receptor antibody (AChR-Ab)-positive myasthenia gravis patients, respectively. For downstream analysis, we applied a machine learning approach. Protein expression levels were confirmed by ELISA and compared to other myasthenic cohorts, in addition to myositis and neuropathy patients. Anti-AChR-Ab levels were determined by a radio receptor assay. Immunohistochemistry and immunofluorescence of intercostal muscle biopsies were employed for validation in addition to interactome studies of inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3). Machine learning identified ITIH3 as potential serum biomarker reflective of disease activity. Serum levels correlated with disease activity scores in the exploration and validation cohort and were confirmed by ELISA. Lack of correlation between anti-AChR-Ab levels and clinical scores underlined the need for biomarkers. In a subgroup analysis, ITIH3 was indicative of treatment responses. Immunostaining of muscle specimens from these patients demonstrated ITIH3 localization at the neuromuscular endplates in myasthenia gravis but not in controls, thus providing a structural equivalent for our serological findings. Immunoprecipitation of ITIH3 and subsequent proteomics lead to identification of its interaction partners playing crucial roles in neuromuscular transmission. This study provides data on ITIH3 as a potential pathophysiological-relevant biomarker of disease activity in myasthenia gravis. Future studies are required to facilitate translation into clinical practice.<\/jats:p>","DOI":"10.1007\/s00401-024-02754-6","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T08:01:56Z","timestamp":1718697716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-7817","authenticated-orcid":false,"given":"Christina B.","family":"Schroeter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Huntemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Preusse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Dobelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Theissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"R\u00e4uber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Willison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vogelsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela Della","family":"Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix F.","family":"Konen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"St\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gereon","family":"Poschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"2754_CR1","doi-asserted-by":"publisher","first-page":"16922","DOI":"10.1074\/jbc.M808560200","volume":"284","author":"JE Adair","year":"2009","unstructured":"Adair JE, Stober V, Sobhany M, Zhuo L, Roberts JD, Negishi M et al (2009) Inter-\u03b1-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J Biol Chem 284:16922\u201316930. https:\/\/doi.org\/10.1074\/jbc.M808560200","journal-title":"J Biol Chem"},{"key":"2754_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","volume":"13","author":"C Barnett","year":"2012","unstructured":"Barnett C, Katzberg H, Nabavi M, Bril V (2012) The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers. J Clin Neuromuscul Dis 13:201\u2013205. https:\/\/doi.org\/10.1097\/CND.0b013e31824619d5","journal-title":"J Clin Neuromuscul Dis"},{"key":"2754_CR3","doi-asserted-by":"publisher","DOI":"10.1214\/07-STS242","author":"P B\u00fchlmann","year":"2007","unstructured":"B\u00fchlmann P, Hothorn T (2007) Boosting algorithms regularization, prediction and model fitting. Statist Sci. https:\/\/doi.org\/10.1214\/07-STS242","journal-title":"Statist Sci"},{"key":"2754_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nprot.2016.042","volume":"11","author":"U Distler","year":"2016","unstructured":"Distler U, Kuharev J, Navarro P, Tenzer S (2016) Label-free quantification in ion mobility\u2013enhanced data-independent acquisition proteomics. Nat Protoc 11:795\u2013812. https:\/\/doi.org\/10.1038\/nprot.2016.042","journal-title":"Nat Protoc"},{"key":"2754_CR5","doi-asserted-by":"publisher","first-page":"567084","DOI":"10.3389\/fnmol.2020.567084","volume":"13","author":"N Eiber","year":"2020","unstructured":"Eiber N, Fr\u00f6b F, Schowalter M, Thiel C, Clemen CS, Schr\u00f6der R et al (2020) Lack of desmin in mice causes structural and functional disorders of neuromuscular junctions. Front Mol Neurosci 13:567084. https:\/\/doi.org\/10.3389\/fnmol.2020.567084","journal-title":"Front Mol Neurosci"},{"key":"2754_CR6","doi-asserted-by":"publisher","first-page":"e0264489","DOI":"10.1371\/journal.pone.0264489","volume":"17","author":"ML Fichtner","year":"2022","unstructured":"Fichtner ML, Hoarty MD, Vadysirisack DD, Munro-Sheldon B, Nowak RJ, O\u2019Connor KC (2022) Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. PLoS ONE 17:e0264489. https:\/\/doi.org\/10.1371\/journal.pone.0264489","journal-title":"PLoS ONE"},{"key":"2754_CR7","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176347963","author":"JH Friedman","year":"1991","unstructured":"Friedman JH (1991) Multivariate adaptive regression splines. Ann Statist. https:\/\/doi.org\/10.1214\/aos\/1176347963","journal-title":"Ann Statist"},{"key":"2754_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0167-9473(01)00065-2","volume":"38","author":"JH Friedman","year":"2002","unstructured":"Friedman JH (2002) Stochastic gradient boosting. Comput Stat Data Anal 38:367\u2013378. https:\/\/doi.org\/10.1016\/S0167-9473(01)00065-2","journal-title":"Comput Stat Data Anal"},{"key":"2754_CR9","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.4049\/jimmunol.179.6.4187","volume":"179","author":"S Garantziotis","year":"2007","unstructured":"Garantziotis S, Hollingsworth JW, Ghanayem RB, Timberlake S, Zhuo L, Kimata K et al (2007) Inter-alpha-trypsin inhibitor attenuates complement activation and complement-induced lung injury. J Immunol 179:4187\u20134192. https:\/\/doi.org\/10.4049\/jimmunol.179.6.4187","journal-title":"J Immunol"},{"key":"2754_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"2754_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Prim 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Prim"},{"key":"2754_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26703","author":"A Gonzalez Garcia","year":"2019","unstructured":"Gonzalez Garcia A, Tutmaher MS, Upadhyayula SR, Sanchez Russo R, Verma S (2019) Novel PLEC gene variants causing congenital myasthenic syndrome. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.26703","journal-title":"Muscle Nerve"},{"key":"2754_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","volume":"139","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann S, Harms L, Schuelke M, R\u00fcckert J-C, Goebel H-H, Stenzel W et al (2020) Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol 139:1119\u20131122. https:\/\/doi.org\/10.1007\/s00401-020-02147-5","journal-title":"Acta Neuropathol"},{"key":"2754_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00180-012-0382-5","volume":"29","author":"B Hofner","year":"2014","unstructured":"Hofner B, Mayr A, Robinzonov N, Schmid M (2014) Model-based boosting in R: a hands-on tutorial using the R package mboost. Comput Stat 29:3\u201335. https:\/\/doi.org\/10.1007\/s00180-012-0382-5","journal-title":"Comput Stat"},{"key":"2754_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"2754_CR16","doi-asserted-by":"publisher","first-page":"5069614","DOI":"10.1155\/2019\/5069614","volume":"2019","author":"X Jiang","year":"2019","unstructured":"Jiang X, Bai X-Y, Li B, Li Y, Xia K, Wang M et al (2019) Plasma inter-alpha-trypsin inhibitor heavy chains H3 and H4 serve as novel diagnostic biomarkers in human colorectal cancer. Dis Markers 2019:5069614. https:\/\/doi.org\/10.1155\/2019\/5069614","journal-title":"Dis Markers"},{"key":"2754_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000092424","volume":"34","author":"RM Kini","year":"2005","unstructured":"Kini RM (2005) Serine proteases affecting blood coagulation and fibrinolysis from snake venoms. Pathophysiol Haemost Thromb 34:200\u2013204. https:\/\/doi.org\/10.1159\/000092424","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2754_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","volume":"92","author":"Y Kojima","year":"2021","unstructured":"Kojima Y, Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H et al (2021) Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. J Neurol Neurosurg Psychiatry 92:963\u2013968. https:\/\/doi.org\/10.1136\/jnnp-2020-325511","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2754_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4143\/crt.2016.550","volume":"50","author":"E-J Lee","year":"2018","unstructured":"Lee E-J, Yang S-H, Kim K-J, Cha H, Lee SJ, Kim J-H et al (2018) Inter-alpha inhibitor H4 as a potential biomarker predicting the treatment outcomes in patients with hepatocellular carcinoma. Cancer Res Treat 50:646\u2013657. https:\/\/doi.org\/10.4143\/crt.2016.550","journal-title":"Cancer Res Treat"},{"key":"2754_CR20","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L et al (2022) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol 269:3050\u20133063. https:\/\/doi.org\/10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"2754_CR21","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1182\/blood-2011-02-337568","volume":"118","author":"TG Loof","year":"2011","unstructured":"Loof TG, M\u00f6rgelin M, Johansson L, Oehmcke S, Olin AI, Dickneite G et al (2011) Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 118:2589\u20132598. https:\/\/doi.org\/10.1182\/blood-2011-02-337568","journal-title":"Blood"},{"key":"2754_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1369\/0022155420940067","volume":"68","author":"MS Lord","year":"2020","unstructured":"Lord MS, Melrose J, Day AJ, Whitelock JM (2020) The inter-\u03b1-trypsin inhibitor family: versatile molecules in biology and pathology. J Histochem Cytochem 68:907\u2013927. https:\/\/doi.org\/10.1369\/0022155420940067","journal-title":"J Histochem Cytochem"},{"key":"2754_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R et al (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. https:\/\/doi.org\/10.1007\/s00415-023-11699-x","journal-title":"J Neurol"},{"key":"2754_CR24","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95:e1617\u2013e1628. https:\/\/doi.org\/10.1212\/WNL.0000000000010574","journal-title":"Neurology"},{"key":"2754_CR25","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1091\/mbc.e14-06-1174","volume":"25","author":"E Mihailovska","year":"2014","unstructured":"Mihailovska E, Raith M, Valencia RG, Fischer I, Banchaabouchi MA, Herbst R et al (2014) Neuromuscular synapse integrity requires linkage of acetylcholine receptors to postsynaptic intermediate filament networks via rapsyn\u2013plectin 1f complexes. MBoC 25:4130\u20134149. https:\/\/doi.org\/10.1091\/mbc.e14-06-1174","journal-title":"MBoC"},{"key":"2754_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2307\/2344614","volume":"135","author":"JA Nelder","year":"1972","unstructured":"Nelder JA, Wedderburn RWM (1972) Generalized Linear Models. J Royal Stat Soc Ser A (General) 135:370. https:\/\/doi.org\/10.2307\/2344614","journal-title":"J Royal Stat Soc Ser A (General)"},{"key":"2754_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","volume":"93","author":"C Nelke","year":"2022","unstructured":"Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N et al (2022) Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 93:548\u2013554. https:\/\/doi.org\/10.1136\/jnnp-2021-328665","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2754_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N et al (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflammation 19:89. https:\/\/doi.org\/10.1186\/s12974-022-02448-4","journal-title":"J Neuroinflammation"},{"key":"2754_CR29","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s41467-024-45099-0","volume":"15","author":"I N\u00fa\u00f1ez-Carpintero","year":"2024","unstructured":"N\u00fa\u00f1ez-Carpintero I, Rigau M, Bosio M, O\u2019Connor E, Spendiff S, Azuma Y et al (2024) Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in congenital myasthenic syndromes. Nat Commun 15:1227. https:\/\/doi.org\/10.1038\/s41467-024-45099-0","journal-title":"Nat Commun"},{"key":"2754_CR30","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1212\/NXI.0000000000001169","volume":"9","author":"AH Obaid","year":"2022","unstructured":"Obaid AH, Zografou C, Vadysirisack DD, Munro-Sheldon B, Fichtner ML, Roy B et al (2022) Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 9:e1169. https:\/\/doi.org\/10.1212\/NXI.0000000000001169","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2754_CR31","doi-asserted-by":"publisher","first-page":"20100","DOI":"10.1074\/jbc.M111.324913","volume":"287","author":"M Okroj","year":"2012","unstructured":"Okroj M, Holmquist E, Sj\u00f6lander J, Corrales L, Saxne T, Wisniewski H-G et al (2012) Heavy chains of inter alpha inhibitor (I\u03b1I) inhibit the human complement system at early stages of the cascade. J Biol Chem 287:20100\u201320110. https:\/\/doi.org\/10.1074\/jbc.M111.324913","journal-title":"J Biol Chem"},{"key":"2754_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ene.14500","volume":"28","author":"Y Ozawa","year":"2021","unstructured":"Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Oda F, Himuro K et al (2021) Changes in serum complements and their regulators in generalized myasthenia gravis. Eur J Neurol 28:314\u2013322. https:\/\/doi.org\/10.1111\/ene.14500","journal-title":"Eur J Neurol"},{"key":"2754_CR33","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s00018-008-7565-9","volume":"65","author":"MJ Page","year":"2008","unstructured":"Page MJ, Di Cera E (2008) Serine peptidases: classification, structure and function. Cell Mol Life Sci 65:1220\u20131236. https:\/\/doi.org\/10.1007\/s00018-008-7565-9","journal-title":"Cell Mol Life Sci"},{"key":"2754_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40478-016-0308-5","volume":"4","author":"C Preu\u00dfe","year":"2016","unstructured":"Preu\u00dfe C, Allenbach Y, Hoffmann O, Goebel H-H, Pehl D, Radke J et al (2016) Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathol Commun 4:45. https:\/\/doi.org\/10.1186\/s40478-016-0308-5","journal-title":"Acta Neuropathol Commun"},{"key":"2754_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02438-z","author":"C Preu\u00dfe","year":"2022","unstructured":"Preu\u00dfe C, Paesler B, Nelke C, Cengiz D, M\u00fcntefering T, Roos A et al (2022) Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-022-02438-z","journal-title":"Acta Neuropathol"},{"key":"2754_CR36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1109\/TPAMI.2009.187","volume":"32","author":"JD Rodriguez","year":"2010","unstructured":"Rodriguez JD, Perez A, Lozano JA (2010) Sensitivity analysis of k-fold cross validation in prediction error estimation. IEEE Trans Pattern Anal Mach Intell 32:569\u2013575. https:\/\/doi.org\/10.1109\/TPAMI.2009.187","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"2754_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L et al (2014) Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 49:483\u2013486. https:\/\/doi.org\/10.1002\/mus.23944","journal-title":"Muscle Nerve"},{"key":"2754_CR38","doi-asserted-by":"publisher","DOI":"10.22004\/AG.ECON.117524","author":"M Schonlau","year":"2005","unstructured":"Schonlau M, Schonlau M (2005) Boosted regression (boosting): an introductory tutorial and a stata plugin. Stata J. https:\/\/doi.org\/10.22004\/AG.ECON.117524","journal-title":"Stata J"},{"key":"2754_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/syn.890030404","volume":"3","author":"R Sealock","year":"1989","unstructured":"Sealock R, Murnane AA, Paulin D, Froehner SC (1989) Immunochemical identification of desmin in Torpedo postsynaptic membranes and at the rat neuromuscular junction. Synapse 3:315\u2013324. https:\/\/doi.org\/10.1002\/syn.890030404","journal-title":"Synapse"},{"key":"2754_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1212\/WNL.0b013e31820882bd","volume":"76","author":"D Selcen","year":"2011","unstructured":"Selcen D, Juel VC, Hobson-Webb LD, Smith EC, Stickler DE, Bite AV et al (2011) Myasthenic syndrome caused by plectinopathy. Neurology 76:327\u2013336. https:\/\/doi.org\/10.1212\/WNL.0b013e31820882bd","journal-title":"Neurology"},{"key":"2754_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.410100506","volume":"10","author":"RS Tindall","year":"1981","unstructured":"Tindall RS (1981) Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 10:437\u2013447. https:\/\/doi.org\/10.1002\/ana.410100506","journal-title":"Ann Neurol"},{"key":"2754_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V (2022) Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 21:189\u2013202. https:\/\/doi.org\/10.1016\/S1474-4422(21)00463-4","journal-title":"Lancet Neurol"},{"key":"2754_CR43","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/jnnp-2021-326480","volume":"92","author":"A Vincent","year":"2021","unstructured":"Vincent A (2021) Using AChR antibody titres to predict treatment responses in myasthenia gravis. J Neurol Neurosurg Psychiatry 92:915. https:\/\/doi.org\/10.1136\/jnnp-2021-326480","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2754_CR44","first-page":"257","volume":"49","author":"A Vincent","year":"1982","unstructured":"Vincent A, Newsom-Davis J (1982) Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 49:257\u2013265","journal-title":"Clin Exp Immunol"},{"key":"2754_CR45","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246\u20131252. https:\/\/doi.org\/10.1136\/jnnp.48.12.1246","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2754_CR46","doi-asserted-by":"publisher","first-page":"e202101099","DOI":"10.26508\/lsa.202101099","volume":"4","author":"F V\u00f6llmy","year":"2021","unstructured":"V\u00f6llmy F, van den Toorn H, Zenezini Chiozzi R, Zucchetti O, Papi A, Volta CA et al (2021) A serum proteome signature to predict mortality in severe COVID-19 patients. Life Sci Alliance 4:e202101099. https:\/\/doi.org\/10.26508\/lsa.202101099","journal-title":"Life Sci Alliance"},{"key":"2754_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13563","volume":"1413","author":"C-A Weis","year":"2018","unstructured":"Weis C-A, Schalke B, Str\u00f6bel P, Marx A (2018) Challenging the current model of early-onset myasthenia gravis pathogenesis in the light of the MGTX trial and histological heterogeneity of thymectomy specimens: EOMG pathogenesis and histological heterogeneity. Ann NY Acad Sci 1413:82\u201391. https:\/\/doi.org\/10.1111\/nyas.13563","journal-title":"Ann NY Acad Sci"},{"key":"2754_CR48","unstructured":"Wiendl H, Meisel A et al (2022) Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie, DGN, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien"},{"key":"2754_CR49","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131487. https:\/\/doi.org\/10.1212\/WNL.52.7.1487","journal-title":"Neurology"},{"key":"2754_CR50","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"key":"2754_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/03008200802325458","volume":"49","author":"L Zhuo","year":"2008","unstructured":"Zhuo L, Kimata K (2008) Structure and function of inter-alpha-trypsin inhibitor heavy chains. Connect Tissue Res 49:311\u2013320. https:\/\/doi.org\/10.1080\/03008200802325458","journal-title":"Connect Tissue Res"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-024-02754-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T08:03:09Z","timestamp":1718697789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-024-02754-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2754"],"URL":"https:\/\/doi.org\/10.1007\/s00401-024-02754-6","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.B.S., C.N., S.G.M., and T.R. have been granted a patent at the European Patent Office (EPO) relating to the use of ITIH3 as a biomarker for (assessing) disease activity in myasthenia gravis patients (application number: EP22195296.3). All other authors have nothing to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"102"}}